Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39


Metformin use and mortality among patients with diabetes and atherothrombosis.

Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S, Ravaud P, Marre M, Porath A, Bhatt DL, Steg PG; Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators.

Arch Intern Med. 2010 Nov 22;170(21):1892-9. doi: 10.1001/archinternmed.2010.409.


Responding to an FDA warning--geographic variation in the use of rosiglitazone.

Shah ND, Montori VM, Krumholz HM, Tu K, Alexander GC, Jackevicius CA.

N Engl J Med. 2010 Nov 25;363(22):2081-4. doi: 10.1056/NEJMp1011042. Epub 2010 Nov 17. No abstract available.


Insiders criticise FDA's decision not to withdraw rosiglitazone.

Cohen D.

BMJ. 2010 Sep 28;341:c5333. doi: 10.1136/bmj.c5333. No abstract available.


Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population.

Wertz DA, Chang CL, Sarawate CA, Willey VJ, Cziraky MJ, Bohn RL.

Circ Cardiovasc Qual Outcomes. 2010 Sep;3(5):538-45. doi: 10.1161/CIRCOUTCOMES.109.911461. Epub 2010 Aug 24.


Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

Nissen SE, Wolski K.

Arch Intern Med. 2010 Jul 26;170(14):1191-1201. doi: 10.1001/archinternmed.2010.207. Review.


Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.

Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA.

JAMA. 2010 Jul 28;304(4):411-8. doi: 10.1001/jama.2010.920. Epub 2010 Jun 28.


Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD).

Bilik D, McEwen LN, Brown MB, Selby JV, Karter AJ, Marrero DG, Hsiao VC, Tseng CW, Mangione CM, Lasser NL, Crosson JC, Herman WH.

Pharmacoepidemiol Drug Saf. 2010 Jul;19(7):715-21. doi: 10.1002/pds.1954.


Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review.

Wang AT, McCoy CP, Murad MH, Montori VM.

BMJ. 2010 Mar 18;340:c1344. doi: 10.1136/bmj.c1344. Review.


Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial.

Gerstein HC, Ratner RE, Cannon CP, Serruys PW, García-García HM, van Es GA, Kolatkar NS, Kravitz BG, Miller DM, Huang C, Fitzgerald PJ, Nesto RW; APPROACH Study Group.

Circulation. 2010 Mar 16;121(10):1176-87. doi: 10.1161/CIRCULATIONAHA.109.881003. Epub 2010 Mar 1.


The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.

Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K.

Clin Ther. 2009 Nov;31(11):2665-77. doi: 10.1016/j.clinthera.2009.11.003.


Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records.

Brownstein JS, Murphy SN, Goldfine AB, Grant RW, Sordo M, Gainer V, Colecchi JA, Dubey A, Nathan DM, Glaser JP, Kohane IS.

Diabetes Care. 2010 Mar;33(3):526-31. doi: 10.2337/dc09-1506. Epub 2009 Dec 15.


Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, Elliott P.

BMJ. 2009 Dec 3;339:b4731. doi: 10.1136/bmj.b4731.


Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study.

Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM.

BMJ. 2009 Aug 18;339:b2942. doi: 10.1136/bmj.b2942.


Rosiglitazone and myocardial infarction in patients previously prescribed metformin.

Dormuth CR, Maclure M, Carney G, Schneeweiss S, Bassett K, Wright JM.

PLoS One. 2009 Jun 27;4(6):e6080. doi: 10.1371/journal.pone.0006080. Erratum in: PLoS One. 2010;5(7). doi: 10.1371/annotation/3330720e-5520-4211-91f3-d3b3d20e9804.


The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.

Acta Diabetol. 2009 Jun;46(2):145-54. doi: 10.1007/s00592-008-0090-3. Epub 2009 Feb 5.


Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.

Stockl KM, Le L, Zhang S, Harada AS.

Pharmacoepidemiol Drug Saf. 2009 Feb;18(2):166-74. doi: 10.1002/pds.1700.


Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.

Loke YK, Singh S, Furberg CD.

CMAJ. 2009 Jan 6;180(1):32-9. doi: 10.1503/cmaj.080486. Epub 2008 Dec 10.


Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.

Winkelmayer WC, Setoguchi S, Levin R, Solomon DH.

Arch Intern Med. 2008 Nov 24;168(21):2368-75. doi: 10.1001/archinte.168.21.2368.


An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients.

Koro CE, Fu Q, Stender M.

Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):989-96. doi: 10.1002/pds.1640.


Supplemental Content

Support Center